We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · November 02, 2020

Efficacy of Subcutaneous Preemptive Rituximab in Immune–Mediated Thrombotic Thrombocytopenic Purpura

American Journal of Hematology

 

Additional Info

American Journal of Hematology
Efficacy of Subcutaneous Preemptive Rituximab in Immune–Mediated Thrombotic Thrombocytopenic Purpura: Experience From the 12 First Cases
Am. J. Hematol 2020 Oct 17;[EPub Ahead of Print], M Delrue, MT Baylatry, AC Joly, E Corre, Z Marjanovic, N El-Khoury-Hanna, F Féger, L Suner, A Veyradier, A Stépanian, P Coppo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading